1 / 12

Endometrial Committee

Endometrial Committee. David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology University of Texas Southwestern Medical Center Dallas, Texas, U.S.A. Resected Endometrial.

lluvia
Download Presentation

Endometrial Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology University of Texas Southwestern Medical Center Dallas, Texas, U.S.A.

  2. Resected Endometrial • GOG0249: A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer (23 Mar 2009) • RTOG

  3. Resected Endometrial • PORTEC 3: Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma • MaNGO, ANZGOG, NRCI, NCIC-CTG, NSGO

  4. Resected Endometrial • GOG258 (UC0704): A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Cancer (29 Jun 2009) • RTOG

  5. Results of previous studies: Study proposal Pooled survival data NSGO The combination of RT + CT is better than RT Proposed new study exploring if the combination of RT and CT is superior to CT: After 4 - A Phase III intergroup trial on adjuvant therapy in radically operated endometrial cancer patients (FIGO stage IC-IIIC) with high risk for micrometastatic disease Thomas Hogberg, Lund Univ Hosp Oct 2009

  6. Proposed study RT Randomization N=1000 Radical surgery TAH+BSO±LA CTx4 CTx2 Main inclusion criteria a. Endometrioid carcinoma b. Stage 1C grade 3 c. Stage IIA grade 3 and MI≥50%, IIB d. Stage IIIA-C Radical surgery, LA recommended but optional Main exclusion criteria Serous or clear cell carcinoma IIIA with only pos fluid cytology CT :Paclitaxel 175 mg/m2, carboplatin AUC 5-6 (calculated) q 3 weeks Primary endpoint Overall survival (OS) Thomas Hogberg, Lund Univ Hosp Oct 2009

  7. Pelvic Recurrence • GOG0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus • RTOG, NCRI, SWOG

  8. EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY Interested Groups: ACRIN, AGO-AUST, AGO-OVAR, ANZGOG?, DUTCH GOG, EORTC, GEICO, GINECO, JGOG, MANGO, MITO, NCRI, NSGO, SWOG

  9. Schema R A N D O M I Z E Women with recurrent or metastatic endometrial cancer 1-2 Prior Chemotherapy Arm 1: ridaforolimus 40 mg po days 1-5 each week Imaging q 8 weeks Disease progression Survival follow-up Arm 2: medroxy progesterone 200 mg or megestrol 160 mg (as per local practice) po daily Chemotherapy options Sample size: Approximately 460 patients

  10. Carcinosarcoma GOG0261: Randomized Phase III Trial of Carboplatin plus Paclitaxel versus Ifosfamide plus Taxol in Patients with Advanced, Persistent or Recurrent Carcinosarcoma NCRI, GINECO, JGOG, RTOG

  11. GTN • Charge from the Executive • RFP • ISSTD

  12. GTD Concepts • Hydatidiform Mole Registry (Quinn) • Pulse Act-D vs. 8 day MTX for Low Risk GTN

More Related